Hsp90 Inhibition Results in Glucocorticoid Receptor Degradation in Association with Increased Sensitivity to Paclitaxel in Triple-Negative Breast Cancer

Targetable molecular drivers for triple-negative breast cancer (TNBC) have been difficult to identify; therefore, standard treatment remains limited to conventional chemotherapy. Recently, new-generation small-molecule Hsp90 inhibitors (e.g., ganetespib and NVP-AUY922) have demonstrated improved saf...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Horm Cancer
Main Authors: Agyeman, Abena S., Jun, Wesley J., Proia, David A., Kim, Caroline R., Skor, Maxwell N., Kocherginsky, Masha, Conzen, Suzanne D.
Formato: Artigo
Idioma:Inglês
Publicado: Springer US 2016
Assuntos:
Original Paper
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC4789079/
https://ncbi.nlm.nih.gov/pubmed/26858237
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s12672-016-0251-8
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares